- Home
- HUYA vs ORIC Comparison
HUYA vs ORIC Comparison
Compare HUYA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUYA
- ORIC
- Stock Information
- Founded
- HUYA 2014
- ORIC 2014
- Country
- HUYA China
- ORIC United States
- Employees
- HUYA N/A
- ORIC N/A
- Industry
- HUYA Computer Software: Programming Data Processing
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- HUYA Technology
- ORIC Health Care
- Exchange
- HUYA Nasdaq
- ORIC Nasdaq
- Market Cap
- HUYA 827.0M
- ORIC 974.1M
- IPO Year
- HUYA 2018
- ORIC 2020
- Fundamental
- Price
- HUYA $3.55
- ORIC $10.52
- Analyst Decision
- HUYA Buy
- ORIC Strong Buy
- Analyst Count
- HUYA 3
- ORIC 10
- Target Price
- HUYA $4.57
- ORIC $17.33
- AVG Volume (30 Days)
- HUYA 1.6M
- ORIC 903.1K
- Earning Date
- HUYA 11-11-2025
- ORIC 11-11-2025
- Dividend Yield
- HUYA 70.64%
- ORIC N/A
- EPS Growth
- HUYA N/A
- ORIC N/A
- EPS
- HUYA N/A
- ORIC N/A
- Revenue
- HUYA $852,782,043.00
- ORIC N/A
- Revenue This Year
- HUYA $8.09
- ORIC N/A
- Revenue Next Year
- HUYA $4.90
- ORIC N/A
- P/E Ratio
- HUYA N/A
- ORIC N/A
- Revenue Growth
- HUYA N/A
- ORIC N/A
- 52 Week Low
- HUYA $2.21
- ORIC $3.90
- 52 Week High
- HUYA $6.43
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- HUYA 54.01
- ORIC 51.83
- Support Level
- HUYA $3.31
- ORIC $10.37
- Resistance Level
- HUYA $3.55
- ORIC $11.16
- Average True Range (ATR)
- HUYA 0.20
- ORIC 0.53
- MACD
- HUYA -0.00
- ORIC 0.03
- Stochastic Oscillator
- HUYA 46.23
- ORIC 46.43
About HUYA HUYA Inc. American depositary shares each representing one ordinary share
Established in 2011, Huya is the largest online game livestreaming company in China. Headquartered in Guangzhou, Huya mainly provides livestreamed videos on esports games such as League of Legends and Honor of Kings and collects virtual tips from viewers. Its products include the Huya Live platform in China and Nimo TV in Southeast Asia and South America. As of 2024, Huya was a subsidiary of Tencent, which owned 63% of its equity stake and held 94% of the voting power.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.